EP0941091A1 - Loratadin und dekongestirum enthaltende zusammensetzung zur behandlung von asthma - Google Patents

Loratadin und dekongestirum enthaltende zusammensetzung zur behandlung von asthma

Info

Publication number
EP0941091A1
EP0941091A1 EP97912874A EP97912874A EP0941091A1 EP 0941091 A1 EP0941091 A1 EP 0941091A1 EP 97912874 A EP97912874 A EP 97912874A EP 97912874 A EP97912874 A EP 97912874A EP 0941091 A1 EP0941091 A1 EP 0941091A1
Authority
EP
European Patent Office
Prior art keywords
loratadine
pseudoephedrine
asthma
milligrams
decongestant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97912874A
Other languages
English (en)
French (fr)
Inventor
Alan G. Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0941091A1 publication Critical patent/EP0941091A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Definitions

  • the invention relates to methods for relieving symptoms of allergic diseases, and more particularly to 5 relieving bronchial asthma symptoms.
  • Asthma is considered to be a very serious chronic allergic disorder, and is typically characterized by airway hyperresponsiveness, recurrent airflow obstruction and symptoms of cough, wheezing and 0 breathlessness . It is one of the most common chronic diseases of childhood, perhaps affecting as many as ten percent of children. Asthma is economically very significant, as it causes considerable time loss from jobs and school, is one of the most common reasons for 5 visits to the physician and is responsible for many admissions to emergency treatment facilities and hospitals. Asthma is also responsible for significant mortality, particularly when not properly treated. It is generally accepted that asthma is 0 characterized by chronic airway inflammation, varying degrees of airway obstruction which is usually reversible, and increases in airway responsiveness to a variety of stimuli. Muscle spasm, airway edema, abnormal mucous production and an inflammatory cell 5 filtrate can often be observed during an acute exacerbation, frequently referred to by sufferers as "an asthma attack.”
  • Airway edema and bronchospasm usually can be successfully treated with bronchodilators, such as epinephrine and the ⁇ 2 -agonists albuterol (also called “salbutamol” ) , metaproterenol , pirbuterol, terbutaline and salmeterol .
  • Airway narrowing can usually be blocked by administering systemic corticosteroids, such as prednisone, or inhaled anti-inflammatory drugs such as beclomethasone dipropionate, flunisolide, triamcinolone acetonide, cromolyn sodium and nedocromil sodium.
  • the /3 2 -agonists are used as daily maintenance medications and as "rescue" medications, when they are administered as needed when exacerbated symptoms are experienced.
  • Systemic corticosteroids are given therapeutically, usually in large doses, for treatment of status asthmaticus, while the corticosteroids are prophylactic and are typically administered for the more severe cases in regular, spaced doses regardless of current symptoms. Action of these treatments results in relief from cough, wheezing and the feeling of breathlessness, plus a reduction in airway narrowing which can easily be quantified by measuring improvements in the patient's forced expiratory volume (FEV) or peak expiratory flow (PEF) rate values; the determination and significance of these parameters are discussed at pages 584-599 of R. Berkow, Ed., The Merck Manual of Diagnosis and Therapy, Fifteenth Edition, Merck Sharp & Dohme Research Laboratories, Rahway, New
  • Antihistamines are weak bronchodilators, and newer agents, many of which are not available in the United States, have some anti- inflammatory properties. They are not as effective as other medications available for the treatment of asthma, and thus do not have a role in routine asthma management.. They are mentioned here, however, to counteract the statements found in many package inserts that antihistamines should not be used in patients with asthma. Their use in patients with upper airway allergies is not contraindicated if the patient has asthma and they may have a beneficial effect on the asthma as well.
  • Terfenadine has also been studied, as reported by. A. Taytard et al . , "Treatment of Bronchial Asthma with Terfenadine; a Randomised Controlled Trial," British Journal of Clinical Pharmacology, Vol. 24, pages 743- 746 (1987); P. Rafferty et al . , "Terfenadine, a Potent Histamine H j ⁇ -Receptor Antagonist in the Treatment of Grass Pollen Sensitive Asthma," British Journal of
  • Decongestant drugs are often used to treat allergic rhinitis. The most significant of these are sympathomimetic amines having Q ⁇ -adrenergic stimulating activity. Among the more widely used orally delivered agents are phenylpropanolamine , ephedrine and pseudoephedrine . Decongestants have long been used in combination with antihistamines for treating allergic and other forms of rhinitis, and some of the publications discussed above relating to cetirizine and terfenadine studies indicate that patients in the antihistamine clinical studies were allowed to use pseudoephedrine for additional relief of symptoms. However, there is no unexpected benefit attributed to this use. SUMMARY OF THE INVENTION
  • the invention encompasses a method for improving pulmonary function of a patient suffering from asthma, comprising administering to the patient the customary rhinitis treatment-effective amounts of loratadine and a decongestant .
  • a preferred decongestant is pseudoephedrine
  • a presently preferred daily treatment for obtaining the desired results of the invention includes 10 milligrams of loratadine and one of: 240 milligrams of pseudoephedrine, administered in a suitable extended release formulation for 24 -hour effectiveness; or two daily doses of 5 milligrams of loratadine and 120 milligrams of pseudoephedrine, administered in an extended release formulation for 12 -hour effectiveness; or in up to four divided doses of immediate release formulations during 24 hours, totalling 10 milligrams of loratadine and 240 milligrams of pseudoephedrine.
  • the individual drugs can be administered separately or in a combination dosage form.
  • Fig. 1 is a graphical representation of morning PEF data obtained in the clinical test of the example.
  • Fig. 2 is a graphical representation of evening PEF data obtained in the clinical test of the example
  • Fig. 3 is a graphical representation of FEV data obtained in the clinical test of the example.
  • a reference herein to "customary rhinitis- effective treatment amounts" of a drug is intended to indicate those doses which are approved by any relevant regulatory agencies, such as the United States Food and Drug Administration, for use of the drug to treat symptoms of allergic rhinitis.
  • References herein to "improving pulmonary function” are meant to include a facilitation of gas exchange processes in the lungs, particularly as shown clinically by improvements in measured FEV and/or PEF values for a patient; such improvements will usually be accompanied by a reduction in the patient's perception of shortness of breath.
  • Loratadine chemically ethyl-4- (8-chloro-5 , 6- dihydro-HH-benzo [5, 6] cyclohepta [1, 2 -b] pyridin-11- ylidene) -1-piperidinecarboxylate with an empirical formula C 22 H 23 C1N 2 0 2 and a molecular weight of 382.89, is a very widely used nonsedating antihistamine drug with a superb safety profile.
  • the active drug and its preparation are described in United States Patent 4,282,233 to Vilani.
  • the drug may also conveniently be prepared according to the process described in United States Patent 4,731,447 to Schumacher et al .
  • loratadine may be administered in any of several dosage forms, including, without limitation, tablets, capsules, syrups or by injection; as with most drugs, oral administration in the form of a tablet or capsule will be preferred for patient convenience.
  • An effective antihistaminic dose of loratadine ranges from about 5 to about 40 milligrams daily. Due to the systemic half-lives of loratadine and its active metabolites, the daily dose may be given once each 24 hours or divided into 2, 3, or 4 preferably equal portions for administration to match the frequency of decongestant drug dosing.
  • a typical daily dose of loratadine for relief of the symptoms of allergic rhinitis is 10 milligrams. Schering Corporation of Kenilworth, New Jersey markets a 10 milligram loratadine tablet under the brand CLARITIN ® .
  • Useful decongestant drugs include topical decongestants and systemic decongestants.
  • Topical decongestants are typically administered in the form of drops or aerosols such as nasal sprays, and contain such drugs as oxymetazoline, phenylephrine, naphazoline, xylometazoline, ephedrine, epinephrine, methylhexaneamine, tetrahydrozoline and xylometazoline. Topical decongestants are not preferred for long-term therapy, due to the eventual appearance of rhinitis medicamentosa which can usually be treated only by discontinuing administration of the drug.
  • Suitable systemic decongestant drug compounds for the practice of the invention include the sympathomimetic amines phenylpropanolamine, ephedrine, pseudoephedrine and phenylephrine, a reference herein to the drug specifically including pharmaceutically acceptable salts thereof, where necessary.
  • the most widely used of these is pseudoephedrine, due to its favorable balance of efficacy and safety; typically, the water-soluble hydrochloride, sulfate or other salts are used to formulate products.
  • Pseudoephedrine sulfate is chemically [S- (R* , R*) ] -a-
  • pseudoephedrine salts may be administered in any of several dosage forms, including, without limitation, tablets, capsules, syrups or by injection; as with most drugs, oral administration in the form of a tablet or capsule will be preferred for patient convenience .
  • pseudoephedrine sulfate or hydrochloride will be administered to adults in daily doses of 120 to 360 milligrams, and to children in daily doses of 60 to 180 milligrams, for the alleviation of congestion from allergic rhinitis.
  • pseudoephedrine is considerably shorter than that of loratadine.
  • immediate release formulations individual doses of 60 milligrams are usually administered to an adult patient four times in each 24 -hour period.
  • extended release solid formulations are known in the art, for example to make 120 milligrams of the drug effective over a 12-hour period, and 240 milligrams effective for a full 24 hours.
  • loratadine and decongestant be dosed together.
  • loratadine can be administered once daily, while the decongestant drug is administered more frequently to maintain a therapeutic systemic drug level. Even when the drugs are dosed together, it is not necessary that they are present in the same formulation or dosage form.
  • Formulations which combine doses of antihistaminic drugs and decongestant drugs are well known in the art .
  • loratadine these include a formulation containing 5 milligrams of loratadine and 60 milligrams of pseudoephedrine sulfate for immediate release from a tablet coating, together with 60 milligrams of pseudoephedrine which is released at a controlled rate from an erodible tablet matrix, for providing effectiveness over a 12 -hour period; a useful product is commercially available in the United States from Schering Corporation of Kenilworth, New Jersey under the brand CLARITIN-D ® 12 HOUR.
  • Another formulation incorporates 10 milligrams of loratadine for immediate release from a tablet coating together with 240 milligrams of pseudoephedrine which is released at a controlled rate from an erodible tablet matrix, for providing effectiveness over a 2 -hour period; this technique is described in United States Patent 5,314,697 to Kwan et al . and a useful product is available in the United States from Schering
  • Fig. 1 shows results from morning measurements of PEF rates for patients receiving loratadine and pseudoephedrine sulfate (solid line) and placebo (broken line) .
  • the ordinate is the mean change of PEF rate from baseline values, expressed in liters per minute.
  • Fig. 2 is a similar representation of results from an evening measurement of PEF rates for the patients, the groups being identified as above. The similar clear, statistically significant improvement during the study is a result of the drug combination administration .
  • Fig. 3 is a representation of further study results, as generated by measurements of FEV in the first second ("FEV. ').
  • the ordinate shows mean change from baseline FEV 1 values, expressed in liters.
  • Data from patients receiving loratadine and pseudoephedrine sulfate are identified by the solid bar, while data from patients receiving only placebo are represented by the open bar.
  • the very clear, statistically significant improvement in pulmonary function during the study is due to the drug combination administration .

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97912874A 1996-10-31 1997-10-29 Loratadin und dekongestirum enthaltende zusammensetzung zur behandlung von asthma Withdrawn EP0941091A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73966996A 1996-10-31 1996-10-31
US739669 1996-10-31
PCT/US1997/019158 WO1998018470A1 (en) 1996-10-31 1997-10-29 Composition, for the treatment of asthma, containing loratadine and a decongestant

Publications (1)

Publication Number Publication Date
EP0941091A1 true EP0941091A1 (de) 1999-09-15

Family

ID=24973307

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97912874A Withdrawn EP0941091A1 (de) 1996-10-31 1997-10-29 Loratadin und dekongestirum enthaltende zusammensetzung zur behandlung von asthma

Country Status (21)

Country Link
EP (1) EP0941091A1 (de)
JP (1) JP2000505104A (de)
KR (1) KR20000052922A (de)
CN (1) CN1235545A (de)
AR (1) AR008908A1 (de)
AU (1) AU731756B2 (de)
BR (1) BR9712705A (de)
CA (1) CA2268546A1 (de)
CO (1) CO4910128A1 (de)
CZ (1) CZ150999A3 (de)
HU (1) HUP9904075A3 (de)
ID (1) ID23431A (de)
IL (1) IL129662A0 (de)
NO (1) NO992062D0 (de)
NZ (1) NZ335078A (de)
PE (1) PE11399A1 (de)
PL (1) PL333056A1 (de)
SK (1) SK54599A3 (de)
TR (1) TR199901003T2 (de)
WO (1) WO1998018470A1 (de)
ZA (1) ZA979731B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021556A1 (en) * 1997-10-29 1999-05-06 J-Med Pharmaceuticals, Inc. Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
CO5271713A1 (es) * 1998-09-10 2003-04-30 Schering Corp Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
KR100505899B1 (ko) * 1999-02-23 2005-08-01 주식회사유한양행 로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
ATE253354T1 (de) * 1999-02-23 2003-11-15 Yuhan Corp Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
AU3924500A (en) * 1999-03-29 2000-10-16 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
WO2001045676A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
WO2001078782A1 (en) * 2000-04-14 2001-10-25 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
PE20020055A1 (es) * 2000-05-25 2002-02-12 Schering Corp Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal
CN1518448A (zh) * 2001-06-20 2004-08-04 ���鹫˾ 用于治疗鼻充血和鼻塞的抗组胺剂
CA2612179C (en) 2005-06-17 2016-08-02 Aft Pharmaceuticals Limited A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion
BRPI0712532A2 (pt) * 2006-06-01 2013-04-02 Schering Plough Healthcare Prod Inc formulaÇÕes e composiÇÕes farmacÊuticas de fenilefrina para absorÇço colânica
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
KR101540191B1 (ko) * 2014-02-24 2015-07-28 성균관대학교산학협력단 로라타딘을 포함하는 항염증용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110397A (en) * 1964-10-02 1968-04-18 Mead Johnson & Co Ephedrine composition
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9818470A1 *

Also Published As

Publication number Publication date
ZA979731B (en) 1998-04-29
NO992062L (no) 1999-04-29
JP2000505104A (ja) 2000-04-25
AR008908A1 (es) 2000-02-23
CN1235545A (zh) 1999-11-17
ID23431A (id) 2000-04-20
KR20000052922A (ko) 2000-08-25
SK54599A3 (en) 2000-08-14
HUP9904075A3 (en) 2002-02-28
TR199901003T2 (xx) 1999-07-21
BR9712705A (pt) 1999-10-26
CZ150999A3 (cs) 1999-10-13
CA2268546A1 (en) 1998-05-07
HUP9904075A2 (hu) 2000-05-28
WO1998018470A1 (en) 1998-05-07
NZ335078A (en) 2000-10-27
AU731756B2 (en) 2001-04-05
AU4995397A (en) 1998-05-22
IL129662A0 (en) 2000-02-29
PE11399A1 (es) 1999-02-09
CO4910128A1 (es) 2000-04-24
NO992062D0 (no) 1999-04-29
PL333056A1 (en) 1999-11-08

Similar Documents

Publication Publication Date Title
AU731756B2 (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
Van As et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate
Aaronson Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma
KR101841442B1 (ko) 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
ZA200500152B (en) Use of reboxetine for the treatment of hot flashes
Bousquet et al. A 12‐week, placebo‐controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis
Georgitis et al. Ipratropium bromide nasal spray in non‐allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life
Kilfeather et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft MistTM Inhaler in patients with COPD
US20030236275A1 (en) Treatment methods of nasal congestion and nasal obstruction
von Berg et al. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma
Davies et al. Efficacy and tolerability comparison of ebastine 10 and 20mg with loratadine 10mg: a double-blind, randomised study in patients with perennial allergic rhinitis
US5376672A (en) Method for treating tension type headaches or headaches associated with drugs or their withdrawal
CA2420532A1 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
McAllen et al. Intranasal flunisolide, placebo and beclomethasone dipropionate in perennial rhinitis
Mattson et al. Preventive effect of ketotifen, a new antiallergic agent, on histamine‐induced bronchoconstriction in asthmatics
Kaiser et al. Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis
Fireman Treatment strategies designed to minimize medical complications of allergic rhinitis
Ishizuka et al. Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma.
Corren et al. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions
MXPA99003936A (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
WO2008079256A2 (en) Methods for treating nasal congestion in hypertensive or diabetic patients
EP1569650B1 (de) Verwendung von levocetirizin zur behandlung von persistierender allergischer rhinitis
Frew et al. Effects of 4-week treatment with low-dose budesonide (100 μg BID) from a novel inhaler AirmaxTM and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma
WO2008085392A1 (en) Methods for treating nasal congestion in hepatically impaired patients
McDonald et al. Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 19990505;LV PAYMENT 19990505;RO PAYMENT 19990505

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010813

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1018941

Country of ref document: HK